Back to search resultsSummaryRMgm-145
|
||||||||
*RMgm-145| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 19000911 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei NK65 |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | A. Combe; T.J. Templeton; R. Menard. |
| Name Group/Department | Unité de Biologie et Génétique du Paludisme |
| Name Institute | Institut Pasteur |
| City | Paris |
| Country | France |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-145 |
| Principal name | TREP- (A1) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Not different from wild type |
| Sporozoite | Normal numbers of midgut sporozoites are formed. Strong reduction in numbers of salivary gland sporozoites. Strong reduction of gliding motility of oocyst-derived/hemolymph sporozoites. Infection of mice/rats by mosquito bite or by inoculation of purified oocyst-derived/hemolymph sporozoites resulted in blood stage infections. |
| Liver stage | Infection of mice/rats by mosquito bite or by inoculation of purified oocyst-derived/hemolymph sporozoites resulted in blood stage infections. |
| Additional remarks phenotype | Mutant/mutation Other mutants lacking expression of TREP has been generated and analysed (see RMgm-159; RMgm-305). In these studies the protein is named S6 or UOS3. These mutants show a comparable phenotype. See also GenBank accession number FJ160771 (S6) and FJ167344 (TREP) for the correct sequence of the gene encoding S6/TREP. |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1306500 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1442600 | ||||||||||||||||||||||||
| Gene product | TRAP-like protein | sporozoite-specific transmembrane protein S6 | ||||||||||||||||||||||||
| Gene product: Alternative name | TREP; TRAP-related protein, S6; sporozoite specific gene 6; UOS3 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | ApaI/AscI | ||||||||||||||||||||||||
| Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | The first PCR product, named «5′TREP», corresponds to the first 606 bp of the open reading frame (ORF) (based on the contig PB000385.03.0) and the second, named «3′TREP», corresponds to a portion of 459 bp of this contig (between position 815 and 1273). | ||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||